Active, not recruitingPhase 1NCT04898894
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Studying Acute leukemia of ambiguous lineage
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Seth Karol, MDSt. Jude Children's Research Hospital
- Intervention
- Venetoclax(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 2-30 years · All sexes
- Timeline
- 2021 – 2027
Study locations (8)
- Rady Children's Hospital-San Diego, San Diego, California, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- UT Southwestern/Simmons Cancer Center, Dallas, Texas, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
Collaborators
Karyopharm Therapeutics Inc · AbbVie · Gateway for Cancer Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04898894 on ClinicalTrials.govOther trials for Acute leukemia of ambiguous lineage
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07046078Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06013423Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesFred Hutchinson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT05761171A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaChildren's Oncology Group
- RECRUITINGPHASE2NCT05901974Venetoclax Combined With Azactidine in the Treatment of ALALSheng-Li Xue, MD
- RECRUITINGPHASE2NCT05735717MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT04099966AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionMitchell Cairo
- RECRUITINGPHASE2NCT04440267Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous LineageInstitute of Hematology & Blood Diseases Hospital, China